Description of Invention:
The present invention identifies a new gene expressed in breast cancers. The gene undergoes alternative splicing, and is expressed as one of two polypeptides. Both splice variants appear to be secreted proteins, and therefore good potential therapeutic targets. The patent application claims BASE polypeptides, nucleic acids, gene therapy and vaccine uses, and antibodies. This novel gene target might be useful as a breast cancer marker for diagnostics, or as a target for breast cancer therapeutics.
Inventors:
Ira Pastan (NCI) Kristi Egland (NCI) James Vincent (NCI) Byungkook Lee (NCI) Robert Strausberg (NCI)
Patent Status:
DHHS Reference No. E-321-2002/0 Licensing Status: This technology is no longer available for licensing.
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-DNA Based Cancer -Diagnostics-In Vitro-MAb Based Cancer -Therapeutics-Immunoconjugates-Mab Cancer -Therapeutics-Gene Therapy-Genes Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: Jasbir (Jesse) S. Kindra J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5559
Email: kindraj@mail.nih.gov
Fax: (301) 402-0220
